Table 4.
Distribution of patient-reported measures in patients with moderate to severe cGvHD
| N (%) | |
|---|---|
| Skin itching | |
| 0 | 55 (28) |
| 1–3 | 50 (26) |
| 4–6 | 30 (16) |
| 7–8 | 10 (5) |
| 9–10 | 7 (4) |
| Mouth dryness | |
| 0 | 43 (22) |
| 1–3 | 57 (30) |
| 4–6 | 18 (9) |
| 7–8 | 21 (11) |
| 9–10 | 12 (6) |
| Mouth pain | |
| 0 | 79 (41) |
| 1–3 | 37 (19) |
| 4–6 | 18 (9) |
| 7–8 | 6 (3) |
| 9–10 | 10 (5) |
| Mouth sensitivity | |
| 0 | 56 (29) |
| 1–3 | 42 (22) |
| 4–6 | 30 (16) |
| 7–8 | 9 (5) |
| 9–10 | 13 (7) |
| Chief Eye Symptom | |
| 0 | 13 (7) |
| 1–3 | 36 (19) |
| 4–6 | 44 (23) |
| 7–8 | 34 (18) |
| 9–10 | 17 (9) |
| 4-point patient global score | |
| 0 | 0 (0) |
| 1 | 42 (22) |
| 2 | 75 (39) |
| 3 | 31 (16) |
| 11-point patient-reported global symptom severity score | |
| 0 | 4 (2) |
| 1–3 | 31 (16) |
| 4–6 | 57 (30) |
| 7–8 | 46 (22) |
| 9–10 | 12 (6) |
| Patient changea | |
| − 3 | 4 (2) |
| − 2 | 11 (6) |
| − 1 | 28 (15) |
| 0 | 63 (33) |
| +1 | 19 (10) |
| +2 | 16 (8) |
| +3 | 8 (4) |
a
Patient change in last month. − 3: very much worse, − 2: moderately worse, − 1: a little worse, 0 - about the same, +1: a little better, +2: moderately better, +3: very much better.